Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
In vivo chemical exchange saturation transfer imaging allows early detection of a therapeutic response in glioblastomaRobert Bachoo; Kimmo J Hatanpaa; Elizabeth A Maher; Bruce E Mickey; Dean Sherry; Masaya Takahashi; Edward Pan)
Proceedings of the National Academy of Sciences of the United States of America. 2014;111(12):4542-4547.Abstract
Glioblastoma multiforme (GBM), which account for more than 50% of all gliomas, is among the deadliest of all human cancers. Given the dismal prognosis of GBM, it would be advantageous to identify early biomarkers of a response to therapy to avoid continuing ineffective treatments and to initiate other therapeutic strategies. The present in vivo longitudinal study in an orthotopic mouse model demonstrates quantitative assessment of early treatment response during short-term chemotherapy with temozolomide (TMZ) by amide proton transfer (APT) imaging. In a GBM line, only one course of TMZ (3 d exposure and 4 d rest) at a dose of 80 mg/kg resulted in substantial reduction in APT signal compared with untreated control animals, in which the APT signal continued to increase. Although there were no detectable differences in tumor volume, cell density, or apoptosis rate between groups, levels of Ki67 (index of cell proliferation) were substantially reduced in treated tumors. In another TMZ-resistant GBM line, the APT signal and levels of Ki67 increased despite the same course of TMZ treatment. As metabolite changes are known to occur early in the time course of chemotherapy and precede morphologic changes, these results suggest that the APT signal in glioma may be a useful functional biomarker of treatment response or degree of tumor progression. Thus, APT imaging may serve as a sensitive biomarker of early treatment response and could potentially replace invasive biopsies to provide a definitive diagnosis. This would have a major impact on the clinical management of patients with glioma.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
D.M. Kokkinakis; R.M. Hoffman; E.P. Frenkel; J.B. Wick; Q. Han; M. Xu; Y. Tan; S.C. ScholdCancer Research. 2001;61(10):4017-4023.
Calin O. Marian; Steve K. Cho; Brian M. Mcellin; Elizabeth A. Maher; Kimmo J. Hatanpaa; Christopher J. Madden; Bruce E. Mickey; Woodring E. Wright; Jerry W. Shay; Robert M. BachooClinical Cancer Research. 2010;16(1):154-163.
Alexander H. Stegh; Hyunggee Kim; Robert M. Bachoo; Kristin L. Forloney; Jean Zhang; Harald Schulze; Kevin Park; Gregory J. Hannon; Junying Yuan; David N. Louis; et al.Genes and Development. 2007;21(1):98-111.
Appears in this Document